HD+ / Outset Medical

StarFish Contribution

Home Dialysis Plus (HD+) engaged StarFish Medical to develop and prototype their novel haemodialysis system aimed at the home market. The goal was a to enable a major improvement in convenience and performance of dialysis. StarFish was involved from concept to the build of the first fully integrated dialysis system prototype.

$100M Valuation

The StarFish prototype successfully demonstrated feasibility and enabled HD+ to attract major funding from private equity banker Warburg Pincus in 2010. After the initial major round, CEO Leslie Trigg pivoted the company to serve clinics. HD+ expanded, changed its name to Outset Medical and was able to raise $278M in a September 2020 IPO. As of March 2021 the company had a capitalization of over $2B.

HD+ dialysis system prototype with integrated touchscreen and fluid management components

The prototype system provided daily nocturnal dialysis combined with a number of novel features including mixing dialysate.

Headshot of Michael Baker, founding CEO of Home Dialysis Plus

Michael Baker
Home Dialysis Plus founding CEO

HD+ early prototype showing fluid mixing components and dialysis control system

StarFish prototype.

Outset Medical Tablo dialysis machine in a clinical environment

Outset is the creator of a product called Tablo, a dialysis machine that simplifies and refines the dialysis process.